FDA Advisers Reject Nuplazid for Alzheimer's Disease Psychosis
Weak trial data not enough to persuade panel to recommend approval
Source: medpagetoday.com
Stay updated with breaking news from Paul Stander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Weak trial data not enough to persuade panel to recommend approval